You just read:

Array BioPharma Announces Positive Top-Line Results from Part 2 of the Phase 3 COLUMBUS Study of Binimetinib and Encorafenib for BRAF-Mutant Melanoma

News provided by

Array BioPharma

May 09, 2017, 16:01 ET